Choreo LLC purchased a new stake in shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 160,867 shares of the company’s stock, valued at approximately $204,000. Choreo LLC owned 0.29% of Connect Biopharma at the end of the most recent quarter.
Separately, BML Capital Management LLC raised its stake in Connect Biopharma by 2.4% during the third quarter. BML Capital Management LLC now owns 2,093,232 shares of the company’s stock valued at $3,014,000 after buying an additional 49,984 shares in the last quarter. 58.72% of the stock is currently owned by institutional investors.
Connect Biopharma Stock Performance
Shares of NASDAQ CNTB opened at $0.92 on Friday. The stock’s 50 day moving average price is $1.06 and its two-hundred day moving average price is $1.14. Connect Biopharma Holdings Limited has a 52-week low of $0.91 and a 52-week high of $2.66.
Connect Biopharma Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Further Reading
- Five stocks we like better than Connect Biopharma
- Consumer Staples Stocks, Explained
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Transportation Stocks Investing
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Stock Dividend Cuts Happen Are You Ready?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.